HENDERSON, Nev., Aug. 29, 2007 (PRIME NEWSWIRE) -- BodyTel Scientific, Inc. (OTCBB:BDYT), a company focused on the development of innovative wireless healthcare products, today announced that they will be attending the first Primary Healthcare Exhibition and Congress at the Abu Dhabi National Exhibition Centre in the United Arab Emirates September 2-4. At the event, BodyTel Scientific will be showcasing their flagship telemedicine-based diabetes self-management solution, GlucoTel at booth 4D10.
The event is focusing on Metabolic Syndrome and associated diseases, and is supported by the UAE Ministry of Health, the Health Authority - Abu Dhabi and the Department of Health and Medical Services (DOHMS) in Dubai, which are responsible for improving the quality of health services in the Emirate and establishing policies in the areas of curative, clinical and preventive medical services.
"In the UAE alone, over 25 percent of the population between the ages of 40-59 suffers from diabetes," states BodyTel Scientific, President and CEO, Stefan Schraps. "With the company pursuing the CE Certification and the U.S. Food & Drug Administration's (FDA) approval to market our blood glucose monitoring device internationally, this is an ideal venue to continue our product awareness campaign. Diabetes truly is a global problem and we are taking the necessary steps to launch our GlucoTel system worldwide towards the end of the calendar year."
BodyTel will have conforming samples on exhibit at the Congress, which brings together doctors working in the primary healthcare sector, along with specialists and other health professionals who treat people with diabetes, obesity and cardiovascular problems. Leading experts will share their expertise, the most recent findings, current practices and evidence-based guidelines on the diagnosis, treatment, and management of Metabolic Syndrome.
BodyTel's GlucoTel Meter is the first and only blood glucose monitoring device in the world with integrated Bluetooth(tm) technology. The meter is part of the GlucoTel system, a complete telemedical diabetes self-management system supporting patients and doctors in the treatment of diabetes. The GlucoTel blood glucose meter collects blood sugar readings and transmits them automatically via Bluetooth to the patient's mobile phone. The data is then sent via SMS (text message) or GPRS (data package) to an Internet database and stored long-term.
About BodyTel Scientific, Inc.
BodyTel Scientific, Inc. is a company focused on the development of innovative wireless health monitoring products. Please visit www.bodytel.com for more company information.
Forward-Looking Statements
Statements regarding the Company's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties that could cause actual results to differ materially from the potential results discussed in the forward-looking statements. Forward-looking statements in this press release include that we are taking the necessary steps to launch our GlucoTel system worldwide towards the end of the calendar year, that the GlucoTel Meter is the first and only blood glucose monitoring device in the world with integrated Bluetooth(tm) technology. The meter is part of the GlucoTel system, a complete telemedical diabetes self-management system supporting patients and doctors in the treatment of diabetes. Actual results may differ materially from those currently anticipated due to a number of factors as we may find that our products must compete with cheaper or better products; we may not be able to retain key employees; a bigger market may not develop for our products and we may not be able to continue to attract new customers; we may face litigation if our technology fails to work when required; our intellectual property may be attacked and defeated in court proceedings; our patent and FDA/CE filings may be rejected by the patent offices and regulators; other companies may discover and develop better or cheaper technologies that would render our products obsolete and we may not have sufficient funding to further develop and/or market our technology. Readers are directed to the BodyTel Scientific, Inc.'s reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its 8-K filed December 14, 2006 under our prior name Sellcell.net which outlined the company's current business for further information and factors that may affect BodyTel Scientific Inc.'s business and results of operations as well as the Company's form 10-KSB filed on December 15, 2006 and the Company's form 10-QSB filed on January 16, 2007. BodyTel Scientific Inc. undertakes no obligations to publicly update any forward-looking statements to reflect future events or circumstances.